- Home
- BYSI vs GNLX Comparison
BYSI vs GNLX Comparison
Compare BYSI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- GNLX
- Stock Information
- Founded
- BYSI 2010
- GNLX 2001
- Country
- BYSI United States
- GNLX United States
- Employees
- BYSI N/A
- GNLX N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- GNLX Health Care
- Exchange
- BYSI Nasdaq
- GNLX Nasdaq
- Market Cap
- BYSI 99.5M
- GNLX 103.6M
- IPO Year
- BYSI 2017
- GNLX 2023
- Fundamental
- Price
- BYSI $1.62
- GNLX $2.36
- Analyst Decision
- BYSI
- GNLX Strong Buy
- Analyst Count
- BYSI 0
- GNLX 4
- Target Price
- BYSI N/A
- GNLX $18.25
- AVG Volume (30 Days)
- BYSI 25.5K
- GNLX 169.7K
- Earning Date
- BYSI 01-01-0001
- GNLX 11-14-2024
- Dividend Yield
- BYSI N/A
- GNLX N/A
- EPS Growth
- BYSI N/A
- GNLX N/A
- EPS
- BYSI N/A
- GNLX N/A
- Revenue
- BYSI $1,876,000.00
- GNLX $8,000.00
- Revenue This Year
- BYSI N/A
- GNLX N/A
- Revenue Next Year
- BYSI N/A
- GNLX N/A
- P/E Ratio
- BYSI N/A
- GNLX N/A
- Revenue Growth
- BYSI 21.03
- GNLX N/A
- 52 Week Low
- BYSI $0.78
- GNLX $1.60
- 52 Week High
- BYSI $4.00
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- BYSI 24.99
- GNLX 37.36
- Support Level
- BYSI $1.85
- GNLX $2.86
- Resistance Level
- BYSI $2.10
- GNLX $3.07
- Average True Range (ATR)
- BYSI 0.17
- GNLX 0.31
- MACD
- BYSI -0.05
- GNLX -0.07
- Stochastic Oscillator
- BYSI 15.02
- GNLX 2.56
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.